Prospective transGEICAM study of the impact of the 21-gene recurrence score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 625-631

  Albanell, J ^a,b   Gonzalez A ^c   Ruiz borrego, M ^d   Alba, E ^e   Garcia saenz J A ^f   Corominas, J M ^a,b   Burgues, O ^g   Furio, V ^f   Rojo, A ^c   Palacios, J ^d   Bermejo, B ^g   Martinez garcia M ^a   Limon, M L ^d   Munoz A S ^e   Martin M ^h   Tusquets, I ^a   Rojo, F ^a,i   Colomer, R ^c   Faull, I ^j   Lluch, A ^g  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^j LiveMedix   (Spain)

more..

Author keywords

Breast cancer; Chemotherapy; Estrogen receptor positive; Oncotype DX; Recurrences Score

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL DECISION MAKING; DISEASE ACTIVITY; ETHNIC GROUP; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MEDICAL SPECIALIST; MULTICENTER STUDY; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RECURRENCE SCORE ASSAY; SCORING SYSTEM; SPANISH; TREATMENT INDICATION;

EID: 84857514854     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr278     Document Type: Article

References (33)

1. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol 2009; 20: 1319-1329.
2. Aebi S, Davidson T, Gruber G et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol 2010; 21 (Suppl 5): v9-v14.
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687-1717.
4. Cronin M, Mylan P, Dutta D et al. Measurement of gene expression in archival paraffin-embedded tissues. Am J Pathol 2004; 164: 35-42.
5. Cronin M, Sangli C, Liu ML et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 2007; 53: 1084-1091.
6. Esteban J, Baker J, Cronin M et al. Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue. Proc Am Soc Clin Oncol 2003; 22: 850. (Abstr).
7. Cobleigh MA, Tabesh B, Bitterman P et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 2005; 11: 8623-8631.
8. Paik S, Shak S, Tang G et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients - NSABP studies B-20 and B-14. Breast Cancer Res Treat 2003; 82: A16. (Abstr).
9. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifentreated, node negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
10. Dowsett M, Cuzick J, Wale C et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study. J Clin Oncol 2010; 28: 1829-1834.
11. Albain K, Barlowe W, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, oestrogenreceptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. Lancet Oncol 2010; 11: 55-65.
12. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734.
13. Harris L, Fritsche H, Mennel R. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
14. NCCN Clinical Practice Guidelines in Oncology Breast Cancer (Version 1. 2011). http://www.NCCN.org (10 January 2011, date last accessed).
15. Oratz R, Paul D, Cohn A et al. Impact of commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. JOP 2007; 3(4): 182-186.
16. Liang H, Brufsky AM, Lembersky BB et al. A retrospective analysis of the impact of oncotype DX low recurrence score results on treatment decisions in a single academic breast cancer center. Cancer Res 2009;; 69 (suppl): (Abst 2061).
17. Erb C, Fox KR, Patel M et al. Evaluation of practice patterns in the treatment of nodenegative, hormone-receptor positive breast cancer patients with the use of Oncotype DX assay at University of Pennsylvania. Cancer Res 2009;; 69 (suppl): (Abst 3082).
18. Asad J, Jacobson A, Estabrook A et al. Does oncotype DX recurrence score affect management of patients with early -stage breast cancer? Am J Surg 2008; 196: 527-529.
19. Henry L, Stojadinovic A, Swain SM et al. The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 2009; 99: 319-323.
20. Lo S, Mumby P, Norton J et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010; 28: 1671-1676.
21. Ademuyiwa FO, Miller A, O'Connor T et al. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat 2011; 126: 797-802.
22. Hassett M, Niland JC, Hughes ME et al. Gene expression profile testing for breast cancer: patterns and predictors of use and impact on chemotherapy. J Clin Oncol 2010; 28: 15s. (Abstr 566).
23. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
24. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
25. Rakha EA, Reis-Filho JS, Baehner F et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010; 12: 207.
26. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23: 7212-7220.
27. Wolf I, Ben-Baruch N, Shapira-Frommer R et al. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients. Cancer 2007; 112: 731-736.
28. Goldstein LJ, Gray R, Badve S et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008; 26: 46063-54071.
29. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
30. Tang G, Cuzick J, Wale C et al. Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: a meta-analysis approach. J Clin Oncol 2010; 28(15s): (Abstr 509).
31. Hornberger J, Lyman G, Chien R. Economic implications of 21-gene recurrence score assay: US multicenter experience. J Clin Oncol 2010; 28: e382.
32. Gianni L, Zambetti M, Clark K Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23: 7265-7277.
33. Badve S, Baehner FL, Gray RP et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008; 26: 2473-2481.